Ventas (NYSE:VTR – Get Rating) had its price target decreased by Royal Bank of Canada from $60.00 to $56.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the real estate investment trust’s stock. Royal Bank of Canada’s price target indicates a potential upside of 24.67% from the stock’s current price.
Several other brokerages have also recently weighed in on VTR. Credit Suisse Group reduced their price target on Ventas from $63.00 to $48.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 1st. StockNews.com cut Ventas from a “hold” rating to a “sell” rating in a research note on Saturday, October 22nd. Robert W. Baird cut Ventas from an “outperform” rating to a “neutral” rating in a research note on Monday, October 10th. Deutsche Bank Aktiengesellschaft reduced their price target on Ventas from $65.00 to $63.00 in a research note on Friday, September 16th. Finally, KeyCorp cut their target price on Ventas from $60.00 to $56.00 and set an “overweight” rating on the stock in a research note on Monday, October 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Ventas presently has an average rating of “Moderate Buy” and a consensus price target of $57.64.
Ventas Price Performance
Shares of Ventas stock opened at $44.92 on Wednesday. The company has a market cap of $17.96 billion, a PE ratio of -408.36, a P/E/G ratio of 3.61 and a beta of 1.13. The business has a 50 day moving average of $40.96 and a 200 day moving average of $47.95. Ventas has a 52 week low of $35.33 and a 52 week high of $64.02. The company has a quick ratio of 0.63, a current ratio of 0.63 and a debt-to-equity ratio of 1.17.
Institutional Inflows and Outflows
Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries – healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population.
- Get a free copy of the StockNews.com research report on Ventas (VTR)
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.